Re: ZEN-3694 Single Agent Trial Status

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: ZEN-3694 Single Agent Trial Status

in response to

Re: ZEN-3694 Single Agent Trial Status

Toinv

posted on Sep 22, 2017 10:30AM

"The challenge is that it needs to be a $120,000,000 plus deal."

Toniv, please explain your $120,000,000 number. The Resverlogix loan is $68 million, right. Where are you coming up with the other $52 million? Is this for future operating costs of Resverlogix? Is this including Resverlogix AND Zenith debit together. Please explain.